Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
复制标题
实验性胰腺癌中存在 [D-TRP6]-黄体生成素释放激素的膜结合位点。
DOI:
10.1016/0304-3835(89)90141-9
复制
发表时间:
1989
期刊:
影响因子:
9.7
通讯作者:
Schally,AV
中科院分区:
文献类型:
--
作者:
Fekete,M;Zalatnai,A;Schally,AV
Characteristics of binding sites (dissociation constant: Kdand maximal binding capacity: Bmax) for [D-Trp6]-luteinizing hormone-releasing hormone ([D-Trp6]-LH-RH]), somatostatin (SS-14) and epidermal growth factor (EGF) were evaluated in membrane fractions of N-Nitrosobis (2-oxopropyl) amine (BOP)-induced pancreatic adenocarcinoma of hamsters. Intact, normal hamster pancreata did not show any binding sites for [D-Trp6]-LH-RH, but specific [D-Trp6]-LH-RH binding sites with low affinity and high capacity were found after pancreatic cancer was induced with BOP. Membrane binding sites for SS-14 and EGF, with high affinity and low capacity were present, both in normal and cancerous pancreata. Normal hamster pancreatic tissue had significantly higher levels of SS-14 binding sites and lower concentration of EGF binding sites as compared to pancreatic carcinoma. In vivo treatment of hamsters bearing pancreatic cancers with microcapsules of agonist [D-Trp6]-LH-RH and the somatostatin analog-RC-160 alone, or in combination, caused histopathological regression of tumors and concomitantly decreased the Kdand Bmaxof [D-Trp6]-LH-RH, and increased the Bmaxof the SS-14 binding sites. These findings represent the first demonstration of binding sites for [D-Trp6]-LH-RH in pancreatic cancers. Our results also suggest that tumor inhibitory effects of [D-Trp6]-LH-RH and RC-160 in pancreatic cancer could be mediated not only indirectly through suppression of sex-steroids, gastrointestinal hormones and growth factors, but also directly by an action on specific binding sites located on the tumor membranes.